gynecologic-cancers-2017-posters-accepted-abstracts

Page 60

conferenceseries

.com

Volume 7, Issue 9 (Suppl)

Gynecol Obstet (Sunnyvale), an open access journal

ISSN: 2161-0932

Gynecologic Cancers 2017

August 29-30, 2017

International Congress on

August 29-30, 2017 | London, UK

Contemporary Issues in

Women Cancers & Gynecologic Oncology

Gynecol Obstet (Sunnyvale) 2017, 7:9 (Suppl)

DOI: 10.4172/2161-0932-C1-019

Investigation of LRRC24, a putative negative regulator of ErbB receptor tyrosine kinases

Amber Andrews, Herman Fennell and Ohoud Alnamais

Hampton University, USA

rrc24 is a 513 amino acid transmembrane protein with a domain organization very similar to Kekkon-1. Preliminary

data from the Fennell lab has revealed that Lrrc24 decreases ErbB receptor expression as efficiently as Lrig1, strongly

suggesting that Lrrc24 is a negative regulator of the ErbB family of RTKs. Furthermore, Lrr24 is expressed in the murine

mammary gland and the epithelium of the healthy human breast but may be decreased in breast cancer. Analysis of the Weigelt

breast cancer dataset demonstrates that Lrrc24 expression inversely correlates with time to metastasis, suggesting that Lrrc24

could be a metastasis suppressor. Furthermore, Lrrc24 is decreased in prostate adenocarcinoma compared to normal prostate.

Collectively, our preliminary data highlight several key features of Lrrc24 which suggest it could be an important growth

suppressor including its ability to negatively regulate oncogenic ErbB RTKs, its expression in normal tissue in which ErbBs are

expressed and its potential loss in cancer. I hypothesize that Lrrc24 is a novel negative regulator of the ErbB family of RTKs and

that it functions to suppress ErbB-driven tumor cell proliferation, motility and/or invasion

Methanolic extract of Pistacia lentiscus (MEPL) as novel therapeutic approach in high-grade serous

ovarian cancer

Charid Imane

University of Bejaia, Algeria

varian cancer remains the most lethal gynecologic cancer in women. More than 60% were diagnosed at advanced stage

and the mortality did not significantly improve over last years. The poor prognosis and high mortality show that the

current therapies often fail and novel approaches are urgently required in order to enhance the prognosis of the disease. In our

study we investigated the effect of the leaves of Pistacia lentisus and Fraxinus angustiforlia, two Algerian medicinal plants used

in traditional medicine since 15th - 16th centuries in ovarian cancer. The different extracts were obtained in different organic

solvents, ethanol, methanol and acetone, and tested towards two ovarian cancer cell lines A2780 and SKOV3. We determine

that the methanolic extract of P. Lentiscus exhibit a cytotoxic potential in A2780 and SKOV3 cells. The active extract (MEPL)

induced apoptosis and cell cycle arrest in these ovarian cancer cell lines. However, the widely used cell lines SKOV-3 and

A2780 were implicated as not being representative of the major HGSC subtype because of the wild-type p53 status. In order

to investigate the mechanism of action (MoA) of MEPL also in patients with the most common subtype of EOC (HGS), we

conducted the preclinical study using newly established primary cell lines from ascites of high grade serous ovarian cancer

patients. The results show that MEPL inhibit PI3K/AKT and MAPK/ERK signaling pathways, and decreased release of IL6 and

VEGF by the malignant cells. Moreover, treatment with MEPL increased the sensitivity to chemotherapy in our primary cell

lines of HGS ovarian cancer patients and might be a promising novel combination therapeutic approach with patients in this

histological subtype of ovarian cancer.